Lipodystrophy in HIV patients: Its challenges and management approaches

HIV/AIDS - Research and Palliative Care

Volumn 3, Issue , 2011, Pages 135-143

  Singhania, Rohit ^a   Kotler, Donald P ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

Body composition; Dyslipidemia; Insulin resistance; Lipoatrophy; Lipohypertrophy

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ORAL ANTIDIABETIC AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; URIDINE;

ADVERSE OUTCOME; ANXIETY; BODY COMPOSITION; BODY FAT; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CONSENSUS; DEPRESSION; DIABETES MELLITUS; DIET THERAPY; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG SAFETY; DYSLIPIDEMIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSTIMULATION; INFLAMMATION; INSULIN RESISTANCE; KINESIOTHERAPY; LIFESTYLE MODIFICATION; LIPOATROPHY; LIPOHYPERTROPHY; LOW CALORY DIET; METABOLIC SYNDROME X; NONHUMAN; PATHOGENESIS; PATIENT COMPLIANCE; PLASTIC SURGERY; RECONSTRUCTIVE SURGERY; REVIEW;

EID: 85014462067     PISSN: None     EISSN: 11791373     Source Type: Journal    
DOI: 10.2147/HIV.S14562     Document Type: Review

References (49)

1. Garg A. Acquired and inherited lipodystrophies. N Engl J Med. 2004; 350: 1220-1234.
2. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS. 1999;13: 2493-2505.
3. Palella FJ, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 1998;43: 27-34.
4. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving protease inhibitors. AIDS. 1998;12: F51-F58.
5. Podzamczer D, Ferrer E, Martínez E, et al. How much fat loss is needed for lipoatrophy to become clinically evident. AIDS Res Hum Retroviruses. 2009;25: 563-567.
6. Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr. 1956;4: 20-23.
7. Bacchetti P, Gripshover B, Grunfeld C, et al. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr. 2005;40: 121-131.
8. Study of fat redistribution and metabolic change in HIV infection (FRAM). Fat distribution in women with HIV infection. J Acquir Immune Defic Syndr. 2006;42: 562-571.
9. Brown TT, Chu H, Wang Z, et al. Longitudinal increases in waist circumference are associated with HIV-serostatus, independent of antiretroviral therapy. AIDS. 2007;21: 1731-1738.
10. Grunfeld C, Pang M, Doerrler W, et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992;74: 1045-1052.
11. Grunfeld C, Kotler DP, Shigenaga JK, et al. Circulating interferon-α levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med. 1991;90: 154-162.
12. Lumpkin MM. FDA public health advisory: reports of diabetes and hyperglycemia in patients receiving protease inhibitors for the treatment of human immunodeficiency virus (HIV). Rockville, MD: US Food and Drug Administration; June 11, 1997.
13. Purnell JQ, Zambon A, Knopp RH, et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS. 2000;14: 51-57.
14. Noor MA, Lo JC, Mulligan K, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS. 2001;15: F11-F18.
15. Maia BS, Engelson ES, Wang J, Kotler DP. Antiretroviral therapy affects the composition of weight loss in HIV infection: implications for clinical nutrition. Clin Nutr. 2005;24: 971-978.
16. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003;289: 2978-2982.
17. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem. 2000; 275: 20251-20254.
18. Liang JS, Distler O, Cooper DA, et al. HIV protease inhibitors protect apolipoprotein B from degradation by the proteosome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med. 2001;7: 1327-1331.
19. McKenzie R, Fried MW, Sallie R, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med. 1995;333: 1099-1105.
20. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292: 191-201.
21. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354: 251-260.
22. Blumer RM, van Vonderen MG, Sutinen J, et al. Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy. AIDS. 2008;22: 227-236.
23. Fleischman A, Johnson S, Systrom DM, et al. Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. Am J Physiol Endocrinol Metab. 2007;292: E1666-E1673.
24. Martin A, Smith SE, Carr A, et al. Reversibility of lipoatrophy in HIVinfected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS. 2004;18: 1029-1036.
25. Franssen R, Sankatsing RR, Hassink E, et al. Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-1 production. Arterioscler Thromb Vasc Biol. 2009; 29: 1336-1341.
26. Ranade K, Geese WJ, Noor M, et al. Genetic analysis implicates resistin in HIV lipodystrophy. AIDS. 2008;22: 1561-1568.
27. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340: 115-126.
28. Deeks SG. HIV infection, inflammation, immunosenescense, and aging. Annu Rev Med. 2011;62: 141-155.
29. El Sadr WM, Lundgren JD, Neaton JD, et al. CD4+count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355: 2283-2296.
30. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5: e203.
31. Calmy A, Gayet-Ageron A, Montecucco F, et al. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS. 2009;23: 929-939.
32. Torriani F, Komarow L, Parker RA, et al. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: the ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol. 2008;52: 569-576.
33. Marin A, Casado JL, Aranzabal L, et al. Validation of a specific questionnaire on psychological and social repercussions of the lipodystrophy syndrome in HIV-infected patients. Qual Life Res. 2006;15: 767-775.
34. Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr. 2001;28: 445-449.
35. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349: 1993-2003.
36. Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV infection? J Acquir Immune Defic Syndr. 2002;30: 471-477.
37. Law MG, Friis-Moller N, El-Sadr WM, et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D: A: D Study. HIV Med. 2006; 7: 218-230.
38. Carr A, Emery S, Law M, et al. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet. 2003; 361: 726-735.
39. Schambelan M, Benson CA, Carr J, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr. 2002;31: 257-275.
40. Wohl DA, McComsey G, Tebas P, et al. Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis. 2006;43: 645-653.
41. Martínez E, Arnaiz JA, Podzamczer D, et al. Substitution of nevirapine, efavirenz, or abacavir for protease. Inhibitors in patients with human immunodeficiency virus infection. N Engl J Med. 2003; 349: 1036-1046.
42. Lazzaretti R, Pinto-Ribeiro J, Kummer R, Polanczyk C, Sprinz E. Dietary intervention when starting HAART prevents the increase in lipids independently of drug regimen: a randomized trial [Abstract WEAB303]. Oral abstract session: 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2007 Jul 22-25; Sydney, Australia.
43. Joy T, Keough HM, Hadigan C, et al. Dietary fat intake and relationship to serum lipid levels among HIV-infected subjects with metabolic abnormalities in the era of HAART. AIDS. 2007;21: 1591-1600.
44. Valantin MA, Aubron-Olivier C, Ghosn J, et al. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS. 2003;17: 2471-2477.
45. Engelson ES, Agin D, Werber-Zion G, et al. Effects of a diet and exercise weight loss regimen on obese, HIV-infected women. Metabolism. 2006;55: 1327-1336.
46. Yarasheski KE, Cade WT, Overton ET, et al. Exercise training augments the peripheral insulin-sensitizing effects of pioglitazone in HIV-infected adults with insulin resistance and central obesity. Am J Physiol Endocrinol Metab. 2011;300: E243-E251.
47. Johannsson G, Marin P, Lonn L, et al. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab. 1997;82: 727-734.
48. Kotler DP, Muurahainen N, Grunfeld C, et al. Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J Acquir Immune Defic Syndr. 2004;35: 239-254.
49. Falutz J, Allas S, Blot K, et al. Effects of a growth hormone releasing factor analogue (growth hormone releasing hormone) on body composition and metabolic indices in HIV-infected patients. N Engl J Med. 2007;357: 2359-2370.